CN109134432A - 氘代抗抑郁药物 - Google Patents
氘代抗抑郁药物 Download PDFInfo
- Publication number
- CN109134432A CN109134432A CN201710450966.9A CN201710450966A CN109134432A CN 109134432 A CN109134432 A CN 109134432A CN 201710450966 A CN201710450966 A CN 201710450966A CN 109134432 A CN109134432 A CN 109134432A
- Authority
- CN
- China
- Prior art keywords
- implementation example
- reference implementation
- iii
- grams
- referring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001430 anti-depressive effect Effects 0.000 title description 7
- 239000000935 antidepressant agent Substances 0.000 title description 7
- 229940005513 antidepressants Drugs 0.000 title description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 8
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims abstract description 5
- 229910052805 deuterium Inorganic materials 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 8
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940073608 benzyl chloride Drugs 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- BPPZXJZYCOETDA-UHFFFAOYSA-N 1-benzylpiperidin-4-ol Chemical compound C1CC(O)CCN1CC1=CC=CC=C1 BPPZXJZYCOETDA-UHFFFAOYSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- -1 N- benzyl -4- hydroxy piperidine ketone Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000005524 benzylchlorides Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000012048 forced swim test Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 2
- 150000008319 1H-pyrimidin-2-ones Chemical class 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AJSHDAOMUKXVDC-UHFFFAOYSA-N butan-1-amine;sulfuric acid Chemical compound CCCC[NH3+].OS([O-])(=O)=O AJSHDAOMUKXVDC-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- GJQNVZVOTKFLIU-UHFFFAOYSA-N piperidin-1-ium-4-one;chloride Chemical class Cl.O=C1CCNCC1 GJQNVZVOTKFLIU-UHFFFAOYSA-N 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710450966.9A CN109134432B (zh) | 2017-06-15 | 2017-06-15 | 氘代抗抑郁药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710450966.9A CN109134432B (zh) | 2017-06-15 | 2017-06-15 | 氘代抗抑郁药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109134432A true CN109134432A (zh) | 2019-01-04 |
CN109134432B CN109134432B (zh) | 2021-06-11 |
Family
ID=64829754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710450966.9A Active CN109134432B (zh) | 2017-06-15 | 2017-06-15 | 氘代抗抑郁药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109134432B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111747926A (zh) * | 2020-06-23 | 2020-10-09 | 浙江华海药业股份有限公司 | 一种羟哌吡酮游离碱的合成工艺改进方法 |
CN112521357A (zh) * | 2020-08-31 | 2021-03-19 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075337A (en) * | 1989-07-26 | 1991-12-24 | G. D. Searle & Co. | Alpha-deuterated 2-alkylaminoacetamide derivatives having reduced toxicity for treatment of CNS disorders |
CN101273024A (zh) * | 2005-07-29 | 2008-09-24 | 康瑟特制药公司 | 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 |
CN101360742A (zh) * | 2005-11-14 | 2009-02-04 | 奥斯拜客斯制药有限公司 | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 |
US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
US20140018436A1 (en) * | 2007-09-13 | 2014-01-16 | Deuterx, Llc | Deuterium-enriched bupropion |
CN106554318A (zh) * | 2015-09-25 | 2017-04-05 | 正大天晴药业集团股份有限公司 | 氘代二苯基氨基嘧啶化合物 |
-
2017
- 2017-06-15 CN CN201710450966.9A patent/CN109134432B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075337A (en) * | 1989-07-26 | 1991-12-24 | G. D. Searle & Co. | Alpha-deuterated 2-alkylaminoacetamide derivatives having reduced toxicity for treatment of CNS disorders |
CN101273024A (zh) * | 2005-07-29 | 2008-09-24 | 康瑟特制药公司 | 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 |
CN101360742A (zh) * | 2005-11-14 | 2009-02-04 | 奥斯拜客斯制药有限公司 | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 |
US20140018436A1 (en) * | 2007-09-13 | 2014-01-16 | Deuterx, Llc | Deuterium-enriched bupropion |
US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
CN106554318A (zh) * | 2015-09-25 | 2017-04-05 | 正大天晴药业集团股份有限公司 | 氘代二苯基氨基嘧啶化合物 |
Non-Patent Citations (2)
Title |
---|
张寅生: "氘代药物研发的过去、现在与未来", 《药学进展》 * |
陈宝军 等: "氚标记盐酸羟哌吡酮的制备", 《中国原子能科学研究院年报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111747926A (zh) * | 2020-06-23 | 2020-10-09 | 浙江华海药业股份有限公司 | 一种羟哌吡酮游离碱的合成工艺改进方法 |
WO2021259051A1 (zh) * | 2020-06-23 | 2021-12-30 | 浙江华海药业股份有限公司 | 一种羟哌吡酮游离碱的合成工艺改进方法 |
CN111747926B (zh) * | 2020-06-23 | 2024-01-30 | 浙江华海药业股份有限公司 | 一种羟哌吡酮游离碱的合成工艺改进方法 |
CN112521357A (zh) * | 2020-08-31 | 2021-03-19 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109134432B (zh) | 2021-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2415849C2 (ru) | Способ получения иматиниба в виде свободного основания или в виде кислотно-аддитивной соли | |
EA023040B1 (ru) | Ингибиторы киназ, регулирующих апоптозный сигнал | |
CN104774194B (zh) | 氘代的丙型肝炎病毒抑制剂 | |
RU2018103332A (ru) | Пиримидиновое соединение с конденсированными кольцами, его промежуточное соединение, способ получения, композиция и применение | |
CN109134432A (zh) | 氘代抗抑郁药物 | |
CN107235916A (zh) | 一种具抗肿瘤活性的甘草查尔酮a硫脲嘧啶类衍生物及其合成方法 | |
AR076969A1 (es) | Un procedimiento para la preparacion de febuxostat | |
CN110407812B (zh) | 一种吲唑哌啶嘧啶类衍生物及其制备方法和用途 | |
CN102321073A (zh) | 一种尼罗替尼的制备方法 | |
EP2575899A1 (en) | Pet radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism | |
US8163907B2 (en) | Dihydropyridine calcium antagonist compounds, preparation methods, and medical uses thereof | |
CN103373986B (zh) | 克里唑替尼前药及其制备方法与用途 | |
RU2761825C1 (ru) | Соединения дейтерированного дефактиниба и их применение | |
CN108947989A (zh) | 氘代光学异构体及其医药用途 | |
CN109776551A (zh) | 二噁烷并喹唑啉衍生物制备方法 | |
CN105272921A (zh) | 一种制备Ceritinib的方法及其中间体化合物 | |
CN106420754B (zh) | 苯并五元氮杂环基哌嗪衍生物的用途 | |
CN106008458A (zh) | 偶氮苯类化合物及其制备方法 | |
CN107011406A (zh) | 一种具有抗肿瘤作用的化合物及其制备方法和应用 | |
CN103012314B (zh) | 磺胺类化合物及其制备方法和应用 | |
CN107311996A (zh) | 一种酰胺化合物及其应用 | |
JP6767382B2 (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
CN104136422A (zh) | 化合物、化合物的制造方法、以及化合物的精制方法 | |
CN103923082B (zh) | 4‑甲氧基‑5‑羟基铁屎米酮衍生物 | |
CN111116551A (zh) | 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210415 Address after: 100070 room 1208, building 3, yard 8, Haiying Road, Fengtai District, Beijing Applicant after: Beijing Junke Huayuan Pharmaceutical Technology Co.,Ltd. Address before: 225312 Room 707, Building D, Phase II, New Drug Creation Base, No. 1 Yaocheng Avenue, Taizhou City, Taizhou City, Jiangsu Province Applicant before: TAIZHOU HUAYUAN MEDICINAL TECH Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Deuterinated antidepressants Effective date of registration: 20231221 Granted publication date: 20210611 Pledgee: Beijing Zhongguancun bank Limited by Share Ltd. Pledgor: Beijing Junke Huayuan Pharmaceutical Technology Co.,Ltd. Registration number: Y2023990000634 |